Oct 19 (Reuters) – CorMedix Inc.: * ANNOUNCES FDA ACCEPTANCE FOR PRIORITY REVIEW OF SUPPLEMENTAL NDA FOR REZZAYO® (REZAFUNGIN) FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASES * FDA GRANTS PRIORITY REVIEW
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oct 19 (Reuters) - Pacific Biosciences of California, Inc.: * PACBIO AND VERILY HEALTH ANNOUNCE…
VIDEO SHOWS: PRESS CONFERENCE WITH MANCHESTER CITY DEFENDER, MARC GUEHI, AND MANCHESTER UNITED MANAGER, ENZO…
Vadodara (Gujarat) [India], October 19: Diplomats in Dialogue 3.0 brought together global diplomacy, higher education…
By Gabriel Araujo SAO PAULO, Oct 19 (Reuters) - Google and McKinsey have agreed to…
BEIJING, Oct 19 (Reuters) - Huawei-affiliated Chinese smart vehicle company Yinwang Intelligent Technology has signed…
(Adds shares in paragraph 2, company comment in bullet 6) By Sneha S K Oct…